Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010019/S087

FOCUS NIGHT AND DAY (LOTRAFILCON A) SOFT CONTACT LENSES

Alcon Laboratories, Inc. · Decision date May 29, 2026

FDA DECISIONP010019/S087

What did the FDA decide?

FDA records P010019/S087 as a supplement to PMA P010019, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 29, 2026.

FDA approval order statement

revise the quality control testing for finished product batch release of lotrafilcon A and B contact lens products
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
May 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P010019/S087
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
May 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P010019/S086 · Related supplement

    Air Optix Plus Hydraglyde (lotrafilcon B) Spherical and Multifocal Soft Contact Lenses for Extended Wear

  2. P010019/S087 received

    Application receipt date recorded by FDA.

  3. P010019/S087 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P010019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010019

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Laboratories, Inc.PMA supplementFeb 26, 2026FDA

Explore the linked device profile

Other records with product code LPM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records